Pioneers of technology agnostic, spatial biology services since 2018. Our experienced team is here to help. Contact us for a free consultation to figure out the best approach for your spatial biology study. NanoString is honored to partner with Macrogen Inc., Propath UK, and Sirona Dx to accelerate access to spatial biology capabilities for biopharma companies around the world. These specialty CROs provide biomarker testing services for drug developers and academic research institutions. https://lnkd.in/g7uzATGF #spatialbiology #BioPharma
Join us at the AACR 2023 Annual Meeting at booth #3442 to learn about our unique spatial-omics service capabilities that span the latest technology platforms. Discuss the best single cell multi-omics approaches for deep immunophenotyping and characterization of the tumor microenvironment to drive biomarker discovery and uncover new opportunities for therapeutic intervention. We look forward to updating you with our latest service capabilities and hear about the latest advances in oncology research from the world’s experts.
Lunaphore and CRO Sirona Dx collaborate to expand COMET offerings to US-based biotech and biopharma customers
LAUSANNE, Switzerland and PORTLAND, OR, USA– February 23, 2023 – 5:00 pm (CET) | 8 am (PST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Sirona Dx, a leader in multi-omics, single-cell analytical services, today announced a strategic collaboration in which Sirona Dx will become the first US-based Contract Research Organization (CRO) to offer Lunaphore’s flagship COMET™ spatial biology platform as a service. COMET™ will complement Sirona Dx’s portfolio of research service offerings to meet the needs of researchers and biopharma teams across various disciplines. Lunaphore’s COMET™ platform is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities. Its capacity allows the generation of high-quality and reproducible data on large cohorts of samples in days. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, enabling customers to use their trusted antibodies and making panel design fast and flexible. Thanks to its versatility, COMET™ has a wide range of research applications across multiple disciplines and all stages of research and drug development. Sirona Dx is a highly-specialized technical CRO and pioneer of single-cell and spatial biology, having launched ultra-high parameter, multiplexed single-cell services to biopharma in 2018. Their innovative, technology-agnostic […]
Scailyte, a single-cell biomarker discovery company and Sirona Dx, a leader in multiomic single-cell analytical services, announce a strategic partnership to accelerate the development of Advanced Therapies. The companies will create a powerful biomarker discovery engine, leveraging Sirona Dx technical and laboratory workflow solutions in combination with Scailyte’s AI-driven data analytics platform ScaiVision™ to serve Biopharma and Biotech. The joint platform will enable discovery and validation of ultra-sensitive biomarkers thanks to Sirona Dx leading technical capabilities in single-cell analysis, and the ability of ScaiVision™ to detect complex molecular signatures in biological samples. The combined workflow will focus on applications within oncology and immunology, including qualification and stratification of patients for clinical trials, analysis of clinical trial results on a deep cellular level or and to advance efficacy and manufacturing processes during CGT development. The first wave of projects with pharmaceutical and diagnostic companies, will begin in Q2-2022. “We are truly excited to partner with Sirona Dx. Precision medicine in Immuno-Oncology is still a challenge today, which requires full mastery and exploitation of the most advanced multi-omics approaches, including single-cell technologies and analytics. With our combined expertise in single-cell technologies applied to translational science, AI and biomarker discovery, we will provide […]
Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine CAMBRIDGE, Mass. & PORTLAND, Ore.–(BUSINESS WIRE)–Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Sirona Dx, a technical contract research organization (CRO), providing advanced, single cell proteomics and genomics services to accelerate the pace of immunotherapy and targeted therapy development, announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and biopharma. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology. “Our InSituPlex technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities offered by Sirona Dx. We believe this joint offering will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery […]
The development of innovative immunotherapy approaches for cancers and autoimmune disorders among others, remains a top priority for Biopharma however numerous challenges create hurdles to progress. To begin with, there is a requirement for multi-faceted, high-parameter, single cell readouts from limited sample inputs to identify informative biomarker signatures. Furthermore, the complex nature of the underlying immunobiology coupled with the multiomic, big data readouts can be difficult to integrate and analyse. Consequently, biopharma companies oftenseek expert guidance on the best approaches including which platforms to utilize, which high parameter multiplexed panels to develop and how best to interrogate the data to gain meaningful insights. Enter Sirona Dx.A CLIA accredited technical contract research organization (CRO), Sirona Dx specializes in high complexity genomics and single cell proteomics services to support pharmaceutical companies with their drug discovery and development programs. Be it for exploratory testing and biomarker development, or clinical trials and companion diagnostics, Sirona Dx offers the latest technologies and expertise to guide clients to the assays and platforms that best match their requirements. A key ingredient of Sirona’s success is their role in bridging the silos between biopharma and the life science tools industry. Leveraging deep relationships with leading life science tools […]
Dr. Nasry Yassa, CEO and Andrew Brown, Chief Commercial Officer, discuss the use of Fluidigm Mass Cytometry technology within their specialty contract research organization. They have created a specialized CRO business that partners with biopharma to accelerate drug development work, with a focus on introducing novel technologies into early clinical stage development. At this event they focus on the adoption of CyTOF and Imaging Mass Cytometry enabling high parameter single cell proteomics readouts to accelerate therapeutic development for their biopharma clients. Listen to webcast
We have implemented advanced microfluidics technology to enable rapid, accurate, lower cost COVID-19 testing on easy to collect saliva samples. The Advanta™ SARS-CoV-2 RT-PCR assay was developed by Fluidigm and is supported by an EUA. The assay is a reverse transcription and real-time polymerase chain reaction (RT-PCR) test that leverages Fluidigm microfluidics technology with the Biomark HD platform. Test results are available within 24h after arrival at our Portland, OR based clinical laboratory.
Sirona Dx is a Portland, Oregon-based technical contract research organization (CRO), which provides high-complexity genomics and proteomics services to pharmaceutical and biotech companies to support drug discovery and development in immuno-oncology. Sirona Dx recently brought the CODEX platform on board to support discovery research with single-cell, spatially resolved multiplex imaging. To learn how the CRO is accelerating drug discovery and development, and how CODEX will help, we spoke to Andrew Brown, PhD, Chief Commercial Officer at Sirona Dx. Tell us about your company – what kinds of projects does Sirona Dx specialize in? Sirona Dx is a CLIA accredited, technology agnostic CRO. We focus primarily on supporting pharma and biotech clients with immunotherapy and targeted therapy programs where there is an acute need for multifaceted, high parameter single cell readouts from limited sample inputs to identify informative biomarker signatures. Why did you decide to set up offices in Portland? In Portland, we have easy access to the West Coast biotech hubs and there’s an incredible scientific talent pool right on our doorstep with OHSU in particular (Oregon Health & Sciences University). While not every member of our team lives in Portland, those who do will confess that Portland and Oregon in general […]
Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore., Nov. 01, 2018 (GLOBE NEWSWIRE) — Sirona Dx, a leader in high-complexity genomics and proteomics services, today announced the introduction of Imaging Mass Cytometry™ services on the Fluidigm Hyperion™ Imaging System to advance biomarker discovery and therapeutic development. Sirona Dx is a specialized contract research organization (CRO) that provides high-quality clinical research services to pharmaceutical and clinical research clients and focuses on offering early access to advanced technologies. With a goal of providing innovative approaches to expand drug discovery pipelines and bring more effective therapies to market, Sirona Dx decided to add multiplex tissue imaging to its growing technology portfolio. Noticing impressive Imaging Mass Cytometry results from top pharmaceutical companies and leading academic medical centers, Sirona Dx engaged Akil Merchant, M.D., Assistant Professor at the University of Southern California Keck School of Medicine, as a Scientific Advisor to assess its full potential. “After a comprehensive evaluation of different tissue imaging technologies, Imaging Mass Cytometry was the clear choice. Imaging Mass Cytometry will enable our clients to resolve complex cellular networks and signaling pathways within tissue microenvironments with unprecedented definition,” said Nasry […]